Company Description
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally.
It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals’ post-stroke.
The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors.
The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024.
Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
| Country | Israel |
| Founded | 2001 |
| IPO Date | Sep 12, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Joshua Hexter |
Contact Details
Address: 3 Hatnufa St., 6th floor Yokneam Illit, 2069203 Israel | |
| Phone | 972 4 959 0123 |
| Website | golifeward.com |
Stock Details
| Ticker Symbol | LFWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607962 |
| CUSIP Number | M8216Q309 |
| ISIN Number | IL0011331076 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Joshua Hexter | Interim Chief Executive Officer |
| Almog Adar | Chief Financial Officer |
| William Mark Grant | Senior Advisor |
| Miri Pariente | Vice President of Operations, Regulatory and Quality |
| Dr. Keith Dale Rose M.D. | Chief Medical Officer |
| Craig Peters DPT | Vice President of Sales - North America |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2026 | PRE 14A | Other preliminary proxy statements |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 8, 2026 | 8-K | Current Report |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 20, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 10, 2026 | EFFECT | Notice of Effectiveness |
| Aug 3, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 8, 2026 | D | Notice of Exempt Offering of Securities |